Search results
Results From The WOW.Com Content Network
Total Health is a new foray for 23andme, but not for the DNA test kit industry as a whole. Ancestry used to maintain a health testing service, which it kicked off in 2019—but the company ...
On Friday it was worth about $3.60 a share. Three-quarters of Lemonaid's $400 million acquisition was paid as shares of 23andMe stock. 23andMe was valued at $3.5 billion when it went public in 2021.
DNA-testing service 23andMe is making substantial efforts to nurse its feeble genetic core back to health. The company will lay off 40% of its workforce, over 200 employees, and cull its therapy ...
Despite operating for nearly two decades without profit, 23andMe went public in 2021 and reached a $6 billion valuation. The company's stocks were priced at $11.13 a share, but they've fallen ...
Genetic testing firm 23andMe said on Monday it is reducing about 40%, or 200 employees, from its workforce and discontinuing further development of all its therapies as part of a restructuring ...
Anne Wojcicki wanted to run things—alone. It was 2009 and her startup 23andMe was riding high, fueled by a steady stream of venture money, intriguing personal accounts of genome exploration, and ...
A spokesperson for 23andMe told Business Insider in a statement that "the company's mission of helping people live longer, healthier lives through a preventive approach to health, and providing ...
NEW YORK (AP) — 23andMe is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costs.